How common is glaucoma, including acute angle‑closure glaucoma, in patients taking sertraline?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Sertraline and Glaucoma: Frequency of Occurrence

Acute angle-closure glaucoma (AACG) associated with sertraline is rare but clinically significant, with patients immediately using SSRIs (including sertraline) having a 5.80-fold increased risk of AACG compared to non-users, and this risk increases to 8.53-fold when daily SSRI doses exceed 20 mg. 1

Incidence and Risk Magnitude

  • The absolute incidence of drug-induced AACG from sertraline remains very low in the general population, though precise population-based rates are not well-established 2, 3
  • A large case-control study from Taiwan (1,465 AACG cases vs 5,712 controls) demonstrated that immediate SSRI users (those receiving prescriptions within 7 days before AACG diagnosis) had an adjusted odds ratio of 5.80 (95% CI: 1.89-17.9) for developing AACG 1
  • Higher doses confer greater risk: patients receiving mean daily SSRI doses exceeding 20 mg had an adjusted OR of 8.53 (95% CI: 1.65-44.0) 1

Mechanism and Clinical Context

The FDA drug label explicitly warns that pupillary dilation from sertraline may trigger an angle-closure attack in patients with anatomically narrow angles who lack a patent iridectomy. 4

  • The mechanism involves pupillary dilation causing iris apposition to the trabecular meshwork in anatomically predisposed eyes 4
  • Most cases occur in individuals unaware they have narrow iridocorneal angles 5
  • Pre-existing open-angle glaucoma is NOT a risk factor for angle-closure glaucoma; the concern is specifically for anatomically narrow angles 4

Underestimation of True Incidence

The actual incidence is likely underestimated because many IOP modifications from SSRIs are pauci-symptomatic or asymptomatic, particularly in cases of intermittent, sub-acute, or progressive angle-closure. 3

  • Case reports and clinical studies suggest visual disturbances leading to SSRI withdrawal may sometimes represent unrecognized IOP changes 3
  • Only dramatic presentations (acute symptomatic AACG) are typically reported, while gradual or intermittent IOP elevations may go undetected 3

High-Risk Populations

Elderly patients with depression are at particularly elevated risk and warrant heightened vigilance. 1

  • Asian populations (particularly Chinese) have higher baseline prevalence of anatomically narrow angles, making them more susceptible 6, 1
  • Patients with anatomical risk factors including hyperopia, shallow anterior chamber depth, short axial length, and thick/anteriorly positioned lens are predisposed 6

Clinical Recommendations

Patients should be advised that sertraline can cause mild pupillary dilation leading to angle-closure glaucoma in susceptible individuals, and may wish to undergo examination to determine susceptibility and consider prophylactic iridectomy if at risk. 4

  • Ophthalmological consultation should be considered before initiating and during SSRI treatment in patients with glaucomatous risk factors, especially elderly patients 3
  • The FDA label specifically instructs prescribers to inform patients about this risk 4

Common Pitfall

The critical error is assuming that patients with diagnosed open-angle glaucoma are at risk for AACG from sertraline—they are not. The risk applies specifically to patients with undiagnosed anatomically narrow angles who can be treated definitively with prophylactic iridectomy if identified before an acute attack occurs 4.

References

2
Research

Acute angle closure glaucoma after sertraline.

General hospital psychiatry, 2013

5
Research

Drug-induced acute angle closure glaucoma.

Current opinion in ophthalmology, 2007

Related Questions

What are the risks of using Selective Serotonin Reuptake Inhibitors (SSRIs) or Norepinephrine Reuptake Inhibitors (NRIs) in patients with glaucoma angle closure?
What is the appropriate intravenous mannitol dose to lower intra‑ocular pressure in an adult with acute angle‑closure glaucoma?
What medications are recommended for managing chronic open‑angle glaucoma and acute angle‑closure glaucoma?
How can acute angle‑closure glaucoma be distinguished from cluster headache based on symptoms, ocular findings, and intra‑ocular pressure?
In a 64-year-old hyperopic woman presenting with sudden severe unilateral ocular pain, headache, nausea, vomiting, blurred vision, halos around lights, and a mid‑dilated sluggish pupil, what is the most likely diagnosis?
How long should Xeroform (petrolatum gauze with bismuth subgallate) be left on a skin tear?
What laboratory tests should be ordered for a patient with chronic kidney disease stage 3a?
How should a child with urticaria triggered by a dog lick be managed?
How should suspected aspiration be managed emergently, including airway protection, oxygen supplementation, imaging, antibiotics, and dysphagia evaluation?
How should I counsel a patient with dysuria and a negative urinalysis about prescribing phenazopyridine (Pyridium) and awaiting urine culture and STI results?
A 20-year-old woman with a serum ferritin of 20 ng/mL who wishes to become pregnant, what daily dose of elemental iron is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.